This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: January 16, 2012
Last updated: November 1, 2016
Last verified: November 2016
This open-label, parallel group study will evaluate the pharmacokinetics and safety of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function. Patients will receive trastuzumab emtansine intravenously on Day 1 of each 3-week cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Condition Intervention Phase
Breast Cancer Drug: trastuzumab emtansine Phase 1

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Pharmacokinetics: Area under the concentration-time curve [ Time Frame: Multiple sampling pre- and up to 21 days post-dose Cycles 1-3 ]

Secondary Outcome Measures:
  • Safety: Incidence of adverse events in patients with mild or moderate hepatic impairment as compared to patients with normal hepatic function [ Time Frame: approximately 2 years ]

Enrollment: 28
Study Start Date: February 2012
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mild hepatic dysfunction Drug: trastuzumab emtansine
Multiple intravenous doses
Experimental: Moderate hepatic dysfunction Drug: trastuzumab emtansine
Multiple intravenous doses
Experimental: Normal hepatic function Drug: trastuzumab emtansine
Multiple intravenous doses


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Histologically or cytologically documented invasive metastatic breast cancer
  • Human epidermal growth factor receptor 2 (HER2) -positive disease
  • Adequate bone marrow and organ function (other than hepatic dysfunction allowed by protocol)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Left ventricular ejection fraction >/=50%
  • Normal hepatic function, or mild to moderate hepatic impairment (Child-Pugh Class A or B)

Exclusion Criteria:

  • History of Grade >/=3 infusion reaction, hypersensitivity reaction, or pneumonitis in response to trastuzumab
  • Investigational therapy or any other anticancer therapy </=28 days before first study treatment
  • Previous treatment with trastuzumab emtansine
  • Brain metastases that are untreated or symptomatic or require therapy to control symptoms or any radiation, surgery or other therapy to control symptoms from brain metastases within 1 month of the first study treatment
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those mentioned above
  • Current peripheral neuropathy of Grade >/=2
  • Child-Pugh Class C hepatic impairment
  • Encephalopathy >/= Grade 2
  • For patients with normal hepatic function: history of drug or alcohol addiction or history of hepatitis B and/or hepatitis C
  • Active hepatitis A, B and/or C
  • Current unstable ventricular arrhythmia requiring treatment
  • History of symptomatic CHF (NYHA Classes II-IV)
  • History of myocardial infarction or unstable angina within 6 months of enrollment
  • History of a decrease in LVEF to<40% or symptomatic CHF with previous trastuzumab treatment
  • Pregnant or lactating women
  • Known HIV infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01513083

United States, Florida
Fort Myers, Florida, United States, 33905
United States, Michigan
Detroit, Michigan, United States, 48201
United States, Oregon
Portland, Oregon, United States, 97239
United States, Tennessee
Nashville, Tennessee, United States, 37203
Canada, Ontario
Ottawa, Ontario, Canada, K1H8L6
Toronto, Ontario, Canada, M5G 2M9
Marseille, France, 13273
Paris, France, 75231
Toulouse, France, 31059
Catanzaro, Calabria, Italy, 88100
Udine, Friuli-Venezia Giulia, Italy, 33100
Barcelona, Spain, 08003
Madrid, Spain, 28007
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01513083     History of Changes
Other Study ID Numbers: BO25499
2011-004591-10 ( EudraCT Number )
Study First Received: January 16, 2012
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Ado-trastuzumab emtansine
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017